期刊文献+

Combined inhibitors of angiogenesis and histone deacetylase:Efficacy in rat hepatoma 被引量:1

Combined inhibitors of angiogenesis and histone deacetylase:Efficacy in rat hepatoma
下载PDF
导出
摘要 AIM:To evaluate the antitumoral effect of combined inhibitors of angiogenesis and histone deacetylases in an experimental rat hepatoma model.METHODS:MH7777A hepatoma cells were injected into the liver of male Buffalo rats.After 7 d treatment with the vascular endothelial growth factor receptor antagonist PTK787/ZK222584(PTK/ZK),the histone deacetylase inhibitor MS-275,tamoxifen(TAM) and/or retinoic acid was initiated(n ≥ 8 animals/group).Natural tumor development was shown in untreated control groups(control 1 with n = 12,control 2 with n = 8).The control groups were initiated at different time points to demonstrate the stability of the hepatoma model.For documentation of possible side effects,we documented any change in body weight,loss of fur and diarrhea.After 21 d treatment,the rats were euthanized.Main target parameters were tumor size and metastasis rate.Additionally,immunohistochemistry for the proliferating cell nuclear antigen(PCNA) and TdT-mediated dUTP-biotin nick end labeling(TUNEL) assay were performed.RESULTS:The control groups developed large tumor nodules with extrahepatic tumor burden in the lung and abdominal organs(control 1:6.18 cm3 ± 4.14 cm3 and control 2:8.0 cm3 ± 4.44 cm3 28 d after tumor cell injection).The tumor volume did not differ significantly in the control groups(P = 0.13).As single agents MS-275 and PTK/ZK reduced tumor volume by 58.6% ± 2.6% and 48.7% ± 3.2% vs control group 1,which was significant only for MS-275(P = 0.025).The combination of MS-275 and PTK/ZK induced a nearly complete and highly significant tumor shrinkage by 90.3% ± 1%(P = 0.005).Addition of TAM showed no further efficacy,while quadruple therapy with retinoic acid increased antitumoral efficacy(tumor reduction by 93 ± 1%) and side effects.PCNA positive cells were not significantly reduced by the single agents,while dual therapy(MS-275 and PTK/ZK) and quadruple therapy reduced the PCNA-positive cell fraction significantly by 9.1 and 20.6% vs control 1(P < 0.05).The number of TUNEL-positive cells,markers for ongoing apoptosis,was increased significantly by the single agents(control 1:6.9%,PTK/ZK:11.4%,MS-275:12.2% with P < 0.05 vs control 1).The fraction of TUNEL-positive cells was upregulated highly significantly by dual therapy(18.4%) and quadruple therapy(24.8%,P < 0.01 vs control 1).For the proliferating(PCNA positive) and apoptotic cell fraction,quadruple therapy was significantly superior to dual therapy(P = 0.01).CONCLUSION:Combined PTK/ZK and MS-275 were highly effective in this hepatoma model.Quadruple therapy enhanced the effects microscopically,but not macroscopically.These results should be investigated further. AIM:To evaluate the antitumoral effect of combined inhibitors of angiogenesis and histone deacetylases in an experimental rat hepatoma model.METHODS:MH7777A hepatoma cells were injected into the liver of male Buffalo rats.After 7 d treatment with the vascular endothelial growth factor receptor antagonist PTK787/ZK222584(PTK/ZK),the histone deacetylase inhibitor MS-275,tamoxifen(TAM) and/or retinoic acid was initiated(n ≥ 8 animals/group).Natural tumor development was shown in untreated control groups(control 1 with n = 12,control 2 with n = 8).The control groups were initiated at different time points to demonstrate the stability of the hepatoma model.For documentation of possible side effects,we documented any change in body weight,loss of fur and diarrhea.After 21 d treatment,the rats were euthanized.Main target parameters were tumor size and metastasis rate.Additionally,immunohistochemistry for the proliferating cell nuclear antigen(PCNA) and TdT-mediated dUTP-biotin nick end labeling(TUNEL) assay were performed.RESULTS:The control groups developed large tumor nodules with extrahepatic tumor burden in the lung and abdominal organs(control 1:6.18 cm3 ± 4.14 cm3 and control 2:8.0 cm3 ± 4.44 cm3 28 d after tumor cell injection).The tumor volume did not differ significantly in the control groups(P = 0.13).As single agents MS-275 and PTK/ZK reduced tumor volume by 58.6% ± 2.6% and 48.7% ± 3.2% vs control group 1,which was significant only for MS-275(P = 0.025).The combination of MS-275 and PTK/ZK induced a nearly complete and highly significant tumor shrinkage by 90.3% ± 1%(P = 0.005).Addition of TAM showed no further efficacy,while quadruple therapy with retinoic acid increased antitumoral efficacy(tumor reduction by 93 ± 1%) and side effects.PCNA positive cells were not significantly reduced by the single agents,while dual therapy(MS-275 and PTK/ZK) and quadruple therapy reduced the PCNA-positive cell fraction significantly by 9.1 and 20.6% vs control 1(P 0.05).The number of TUNEL-positive cells,markers for ongoing apoptosis,was increased significantly by the single agents(control 1:6.9%,PTK/ZK:11.4%,MS-275:12.2% with P 0.05 vs control 1).The fraction of TUNEL-positive cells was upregulated highly significantly by dual therapy(18.4%) and quadruple therapy(24.8%,P 0.01 vs control 1).For the proliferating(PCNA positive) and apoptotic cell fraction,quadruple therapy was significantly superior to dual therapy(P = 0.01).CONCLUSION:Combined PTK/ZK and MS-275 were highly effective in this hepatoma model.Quadruple therapy enhanced the effects microscopically,but not macroscopically.These results should be investigated further.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2011年第31期3623-3629,共7页 世界胃肠病学杂志(英文版)
基金 Supported by The Schering AG,Berlin (Germany) which friendly provided PTK787/ZK222584 and MS-275
关键词 PTK787 ZK222584 MS-275 Hepatocellular carcinoma Histone deacetylase inhibitor 血管生成抑制剂 肝癌细胞 疗效观察 实验大鼠 去乙酰化 组蛋白 增殖细胞核抗原 血管内皮生长因子
  • 相关文献

参考文献3

二级参考文献97

  • 1Zhao-You Tang Liver Cancer Institute & Zhongshan Hospital of Fudan University Professor of Surgery Chairman.Liver Cancer Institute of Fudan University(previous Liver Cancer Institute of Shanghai Medical University)136 Yixueyuan Road,Zhongshan Hospital,Shanghai 200032,China..Hepatocellular Carcinoma-Cause,Treatment and Metastasis[J].World Journal of Gastroenterology,2001,7(4):445-454. 被引量:214
  • 2Zheng-Ping Xiong, Shu-Ren Yang, Zhao-Yu Liang, En-Hua Xiao, Xiao-Ping Yu,Shen-Ke Zhou and Zi-Shu Zhang, Department of Radiology , Hunan Provincial TumorHospital. Changsha 410006, China ,Department of Radiology, Xiangya Second Hospital of Central South Uni-versity, Changsha 410011, China.Association between vascular endothelial growth factor and metastasis after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma[J].Hepatobiliary & Pancreatic Diseases International,2004,3(3):386-390. 被引量:27
  • 3Zhi-Cheng Zhao,Shu-Sen Zheng,Yun-Le Wan,Chang-Ku Jia,Hai-Yang Xie the Department of Hepatobiliary Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.The molecular mechanism underlying angiogenesis in hepatocellular carcinoma: the imbalance activation of signaling pathways[J].Hepatobiliary & Pancreatic Diseases International,2003,2(4):529-536. 被引量:19
  • 4Parkin DM,Bray F,Ferlay J,Pisani P.Estimating the world cancer burden:Globocan 2000.Int J Cancer 2001; 94:153-156.
  • 5Befeler AS,Di Bisceglie AM.Hepatocellular carcinoma:diagnosis and treatment.Gastroenterology 2002; 122:1609-1619.
  • 6Liu JH,Chen PW,Asch SM,Busuttil RW,Ko CY.Surgery for hepatocellular carcinoma:does it improve survival? Ann Surg Oncol 2004; 11:298-303.
  • 7Fong TL,Kanel GC,Conrad A,Valinluck B,Charboneau F,Adkins RH.Clinical significance of concomitant hepatitis C infection in patients with alcoholic liver disease.Hepatology 1994; 19:554-557.
  • 8Ming L,Thorgeirsson SS,Gail MH,Lu P,Harris CC,Wang N,Shao Y,Wu Z,Liu G,Wang X,Sun Z.Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong,China.Hepatology 2002; 36:1214-1220.
  • 9Hassan MM,Hwang LY,Hatten CJ,Swaim M,Li D,Abbruzzese JL,Beasley P,Patt YZ.Risk factors for hepatocellular carcinoma:synergism of alcohol with viral hepatitis and diabetes mellitus.Hepatology 2002; 36:1206-1213.
  • 10Ohata K,Hamasaki K,Toriyama K,Matsumoto K,Saeki A,Yanagi K,Abiru S,Nakagawa Y,Shigeno M,Miyazoe S,Ichikawa T,Ishikawa H,Nakao K,Eguchi K.Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection.Cancer 2003; 97:3036-3043.

共引文献147

同被引文献1

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部